Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs [Yahoo! Finance]
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Yahoo! Finance
Research and Development Costs: $10.6 million for the quarter, up from $3 million in Q3 2023. Selling, General and Administrative Expenses: $35.2 million for the quarter, compared to $13.4 million in Q3 2023. Net Loss After Tax: $43 million for the quarter, compared to $14.7 million in Q3 2023. Loss Per Share: $0.07 per ordinary share or $0.53 per ADS for the quarter. Cash and Equivalents: $336 million as of September 30, 2024. Warning! GuruFocus has detected 2 Warning Sign with VRNA. Release Date: November 04, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Verona Pharma PLC ( NASDAQ:VRNA ) successfully launched Ohtuvayre in the US for COPD treatment, achieving net product sales of $5.6 million in just seven weeks. Over 5,000 Ohtuvayre prescriptions were filled within 12 weeks, with more than 2,200 unique healthcare providers prescribing the medication. Ohtuvayre is being prescribed across a broad range of
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsightPR Newswire
- Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsightPR Newswire
- Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]Yahoo! Finance
- Verona Pharma Announces December 2024 Investor Conference ParticipationGlobeNewswire
- Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]Yahoo! Finance
VRNA
Sec Filings
- 11/18/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- VRNA's page on the SEC website